Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV

Inclusion Criteria: * Histological or cytological proven diagnosis of epithelial ovary cancer F.I.G.O stages III or IV (when only cytological proven diagnosis is available: malignant cells and pelvis tumoral mass and increased CA-125 must be diagnosed simultaneously) * Patient aged \> 70 years * Neutrophil polynuclears \> 1500/mm3 and Platelets \> 100 000/mm3 * No clinical icterus * Life expectancy of at least 3 months Exclusion Criteria: * Previous diagnosis of malignancy * Previous chemotherapy treatment * Previous radiotherapy * Hypersensitivity to products containing Cremophore EL * Hepatic values: bilirubine \> 2\*LSN, SGOT-SGPT \> 2\*LSN and/or Alkalin phosphatase \> 3\*LSN * Myocardiopathy with arrhythmia